| Literature DB >> 15037614 |
Yoichi Araki1, Naomi Miyagi, Naoko Kato, Tomohiro Yoshida, Sachiyo Wada, Masaki Nishimura, Hiroto Komano, Tohru Yamamoto, Bart De Strooper, Kazuo Yamamoto, Toshiharu Suzuki.
Abstract
The Alcadeins (Alcs)/calsyntenins and the amyloid beta-protein precursor (APP) associate with each other in the brain by binding via their cytoplasmic domains to X11L (the X11-like protein). We previously reported that the formation of this APP-X11L-Alc tripartite complex suppresses the metabolic cleavages of APP. We show here that the metabolism of the Alcs markedly resembles that of APP. The Alcs are subjected to a primary cleavage event that releases their extracellular domain. Alcs then undergo a secondary presenilin-dependent gamma-cleavage that leads to the secretion of the amyloid beta-protein-like peptide and the liberation of an intracellular domain fragment (AlcICD). However, when Alc is in the tripartite complex, it escapes from these cleavages, as does APP. We also found that AlcICD suppressed the FE65-dependent gene transactivation activity of the APP intracellular domain fragment, probably because AlcICD competes with the APP intracellular domain fragment for binding to FE65. We propose that the Alcs and APP are coordinately metabolized in neurons and that their cleaved cytoplasmic fragments are reciprocally involved in the regulation of FE65-dependent gene transactivation. Any imbalance in the metabolism of Alcs and APP may influence the FE65-dependent gene transactivation, which together with increased secretion of amyloid beta-protein may contribute to neural disorders.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15037614 DOI: 10.1074/jbc.M401925200
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157